Correction to: Real-World Comparative Effectiveness Study in Patients with Asthma Initiating Fluticasone Furoate/Vilanterol or Beclometasone Dipropionate/Formoterol Fumarate in General Practice in England (Advances in Therapy, (2025), 42, 12, (5960-5977), 10.1007/s12325-025-03349-7)

Abstract

This note corrects an error in Table 6 Comparative effectiveness in subgroup of patients who were on both ICS and SABA at baseline, of the supplement. The original publication inadvertently mentioned the exacerbation rate as PPPY (per person per year) instead of PPPD (per person per day). The correct exacerbation rate for the Primary and Supplementary Estimands in Table 6 is PPPD. The rest of the table remains the same, and the interpretation of the results is unchanged. The original article is corrected.